Home/Pipeline/SAR443820 (Rilzabrutinib)

SAR443820 (Rilzabrutinib)

Immune Thrombocytopenia (ITP)

Phase 3ActiveN/A

Key Facts

Indication
Immune Thrombocytopenia (ITP)
Phase
Phase 3
Status
Active
Company

About Sanofi

Sanofi is a global biopharmaceutical leader with a mission to 'chase the miracles of science' by developing innovative medicines and vaccines. The company has strategically pivoted to become an R&D-driven, AI-powered organization, focusing its deep immunoscience expertise on high-growth areas like immunology and oncology. Its strategy is centered on accelerating drug discovery, optimizing its robust pipeline, and delivering compelling growth through breakthrough therapeutics.

View full company profile

Other Immune Thrombocytopenia (ITP) Drugs

DrugCompanyPhase
CevidoplenibGenoscoPhase not specified